- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer ; volume:40 ; number:1 ; day:19 ; month:3 ; year:2021 ; pages:1-12 ; date:12.2021
Journal of experimental & clinical cancer research ; 40, Heft 1 (19.3.2021), 1-12, 12.2021
- Urheber
-
Noblejas-López, María del Mar
Nieto-Jiménez, Cristina
Galán-Moya, Eva M.
Tebar-García, David
Montero, Juan Carlos
Pandiella, Atanasio
Burgos, Miguel
Ocaña, Alberto
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-021-01907-9
- URN
-
urn:nbn:de:101:1-2021050521215560886091
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Noblejas-López, María del Mar
- Nieto-Jiménez, Cristina
- Galán-Moya, Eva M.
- Tebar-García, David
- Montero, Juan Carlos
- Pandiella, Atanasio
- Burgos, Miguel
- Ocaña, Alberto
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018